nodes	percent_of_prediction	percent_of_DWPC	metapath
Regadenoson—Diarrhoea—Vismodegib—skin cancer	0.0042	0.0042	CcSEcCtD
Regadenoson—Angiopathy—Imiquimod—skin cancer	0.00413	0.00413	CcSEcCtD
Regadenoson—Immune system disorder—Imiquimod—skin cancer	0.00411	0.00411	CcSEcCtD
Regadenoson—Mediastinal disorder—Imiquimod—skin cancer	0.0041	0.0041	CcSEcCtD
Regadenoson—Chest discomfort—Docetaxel—skin cancer	0.00408	0.00408	CcSEcCtD
Regadenoson—Cough—Vemurafenib—skin cancer	0.00405	0.00405	CcSEcCtD
Regadenoson—Mental disorder—Imiquimod—skin cancer	0.00398	0.00398	CcSEcCtD
Regadenoson—Bronchospasm—Bleomycin—skin cancer	0.00397	0.00397	CcSEcCtD
Regadenoson—Erythema—Imiquimod—skin cancer	0.00396	0.00396	CcSEcCtD
Regadenoson—Myalgia—Vemurafenib—skin cancer	0.00395	0.00395	CcSEcCtD
Regadenoson—Arthralgia—Vemurafenib—skin cancer	0.00395	0.00395	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.00393	0.00393	CcSEcCtD
Regadenoson—Vomiting—Vismodegib—skin cancer	0.0039	0.0039	CcSEcCtD
Regadenoson—Rash—Vismodegib—skin cancer	0.00387	0.00387	CcSEcCtD
Regadenoson—Dermatitis—Vismodegib—skin cancer	0.00386	0.00386	CcSEcCtD
Regadenoson—Anaphylactic shock—Vemurafenib—skin cancer	0.00379	0.00379	CcSEcCtD
Regadenoson—Nervous system disorder—Vemurafenib—skin cancer	0.00372	0.00372	CcSEcCtD
Regadenoson—Skin disorder—Vemurafenib—skin cancer	0.00368	0.00368	CcSEcCtD
Regadenoson—Ill-defined disorder—Imiquimod—skin cancer	0.00367	0.00367	CcSEcCtD
Regadenoson—Nausea—Vismodegib—skin cancer	0.00364	0.00364	CcSEcCtD
Regadenoson—Angioedema—Imiquimod—skin cancer	0.00362	0.00362	CcSEcCtD
Regadenoson—Malaise—Imiquimod—skin cancer	0.00357	0.00357	CcSEcCtD
Regadenoson—Syncope—Imiquimod—skin cancer	0.00355	0.00355	CcSEcCtD
Regadenoson—Acute coronary syndrome—Bleomycin—skin cancer	0.00355	0.00355	CcSEcCtD
Regadenoson—Hypotension—Vemurafenib—skin cancer	0.00354	0.00354	CcSEcCtD
Regadenoson—Myocardial infarction—Bleomycin—skin cancer	0.00353	0.00353	CcSEcCtD
Regadenoson—Palpitations—Imiquimod—skin cancer	0.0035	0.0035	CcSEcCtD
Regadenoson—Loss of consciousness—Imiquimod—skin cancer	0.00348	0.00348	CcSEcCtD
Regadenoson—Cough—Imiquimod—skin cancer	0.00345	0.00345	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.00345	0.00345	CcSEcCtD
Regadenoson—Cardiac arrest—Fluorouracil—skin cancer	0.00345	0.00345	CcSEcCtD
Regadenoson—Convulsion—Imiquimod—skin cancer	0.00343	0.00343	CcSEcCtD
Regadenoson—Abdominal distension—Temozolomide—skin cancer	0.00343	0.00343	CcSEcCtD
Regadenoson—Hypertension—Imiquimod—skin cancer	0.00342	0.00342	CcSEcCtD
Regadenoson—Chest pain—Imiquimod—skin cancer	0.00337	0.00337	CcSEcCtD
Regadenoson—Myalgia—Imiquimod—skin cancer	0.00337	0.00337	CcSEcCtD
Regadenoson—Arthralgia—Imiquimod—skin cancer	0.00337	0.00337	CcSEcCtD
Regadenoson—Anxiety—Imiquimod—skin cancer	0.00336	0.00336	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.00335	0.00335	CcSEcCtD
Regadenoson—Discomfort—Imiquimod—skin cancer	0.00333	0.00333	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Vemurafenib—skin cancer	0.00327	0.00327	CcSEcCtD
Regadenoson—Hypoaesthesia—Bleomycin—skin cancer	0.00321	0.00321	CcSEcCtD
Regadenoson—Shock—Imiquimod—skin cancer	0.00318	0.00318	CcSEcCtD
Regadenoson—Nervous system disorder—Imiquimod—skin cancer	0.00317	0.00317	CcSEcCtD
Regadenoson—Tachycardia—Imiquimod—skin cancer	0.00315	0.00315	CcSEcCtD
Regadenoson—Skin disorder—Imiquimod—skin cancer	0.00314	0.00314	CcSEcCtD
Regadenoson—Hyperhidrosis—Imiquimod—skin cancer	0.00312	0.00312	CcSEcCtD
Regadenoson—Angina pectoris—Fluorouracil—skin cancer	0.00306	0.00306	CcSEcCtD
Regadenoson—Flushing—Bleomycin—skin cancer	0.003	0.003	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Imiquimod—skin cancer	0.00294	0.00294	CcSEcCtD
Regadenoson—Insomnia—Imiquimod—skin cancer	0.00292	0.00292	CcSEcCtD
Regadenoson—Paraesthesia—Imiquimod—skin cancer	0.0029	0.0029	CcSEcCtD
Regadenoson—Dyspnoea—Imiquimod—skin cancer	0.00288	0.00288	CcSEcCtD
Regadenoson—Somnolence—Imiquimod—skin cancer	0.00287	0.00287	CcSEcCtD
Regadenoson—Erythema—Bleomycin—skin cancer	0.00281	0.00281	CcSEcCtD
Regadenoson—Flushing—Dactinomycin—skin cancer	0.0028	0.0028	CcSEcCtD
Regadenoson—Hypersensitivity—Vemurafenib—skin cancer	0.00279	0.00279	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Imiquimod—skin cancer	0.00279	0.00279	CcSEcCtD
Regadenoson—Atrial fibrillation—Docetaxel—skin cancer	0.00276	0.00276	CcSEcCtD
Regadenoson—Pain—Imiquimod—skin cancer	0.00276	0.00276	CcSEcCtD
Regadenoson—Acute coronary syndrome—Fluorouracil—skin cancer	0.00276	0.00276	CcSEcCtD
Regadenoson—Renal impairment—Docetaxel—skin cancer	0.00275	0.00275	CcSEcCtD
Regadenoson—Myocardial infarction—Fluorouracil—skin cancer	0.00274	0.00274	CcSEcCtD
Regadenoson—Asthenia—Vemurafenib—skin cancer	0.00272	0.00272	CcSEcCtD
Regadenoson—Hypoaesthesia—Temozolomide—skin cancer	0.00271	0.00271	CcSEcCtD
Regadenoson—Connective tissue disorder—Temozolomide—skin cancer	0.00268	0.00268	CcSEcCtD
Regadenoson—Feeling abnormal—Imiquimod—skin cancer	0.00266	0.00266	CcSEcCtD
Regadenoson—Gastrointestinal pain—Imiquimod—skin cancer	0.00264	0.00264	CcSEcCtD
Regadenoson—Erythema—Dactinomycin—skin cancer	0.00262	0.00262	CcSEcCtD
Regadenoson—Pain in extremity—Docetaxel—skin cancer	0.00262	0.00262	CcSEcCtD
Regadenoson—Ill-defined disorder—Bleomycin—skin cancer	0.00261	0.00261	CcSEcCtD
Regadenoson—Diarrhoea—Vemurafenib—skin cancer	0.00259	0.00259	CcSEcCtD
Regadenoson—Urticaria—Imiquimod—skin cancer	0.00257	0.00257	CcSEcCtD
Regadenoson—Abdominal pain—Imiquimod—skin cancer	0.00255	0.00255	CcSEcCtD
Regadenoson—Eye disorder—Temozolomide—skin cancer	0.00255	0.00255	CcSEcCtD
Regadenoson—Tinnitus—Temozolomide—skin cancer	0.00254	0.00254	CcSEcCtD
Regadenoson—Malaise—Bleomycin—skin cancer	0.00254	0.00254	CcSEcCtD
Regadenoson—Flushing—Temozolomide—skin cancer	0.00253	0.00253	CcSEcCtD
Regadenoson—Cardiac disorder—Temozolomide—skin cancer	0.00253	0.00253	CcSEcCtD
Regadenoson—Dizziness—Vemurafenib—skin cancer	0.00251	0.00251	CcSEcCtD
Regadenoson—Hypoaesthesia—Fluorouracil—skin cancer	0.0025	0.0025	CcSEcCtD
Regadenoson—Angiopathy—Temozolomide—skin cancer	0.00247	0.00247	CcSEcCtD
Regadenoson—Immune system disorder—Temozolomide—skin cancer	0.00246	0.00246	CcSEcCtD
Regadenoson—Mediastinal disorder—Temozolomide—skin cancer	0.00246	0.00246	CcSEcCtD
Regadenoson—Cough—Bleomycin—skin cancer	0.00245	0.00245	CcSEcCtD
Regadenoson—Ill-defined disorder—Dactinomycin—skin cancer	0.00243	0.00243	CcSEcCtD
Regadenoson—Vomiting—Vemurafenib—skin cancer	0.00241	0.00241	CcSEcCtD
Regadenoson—Chest pain—Bleomycin—skin cancer	0.00239	0.00239	CcSEcCtD
Regadenoson—Myalgia—Bleomycin—skin cancer	0.00239	0.00239	CcSEcCtD
Regadenoson—Rash—Vemurafenib—skin cancer	0.00239	0.00239	CcSEcCtD
Regadenoson—Mental disorder—Temozolomide—skin cancer	0.00239	0.00239	CcSEcCtD
Regadenoson—Dermatitis—Vemurafenib—skin cancer	0.00239	0.00239	CcSEcCtD
Regadenoson—Hypersensitivity—Imiquimod—skin cancer	0.00238	0.00238	CcSEcCtD
Regadenoson—Headache—Vemurafenib—skin cancer	0.00237	0.00237	CcSEcCtD
Regadenoson—Erythema—Temozolomide—skin cancer	0.00237	0.00237	CcSEcCtD
Regadenoson—Discomfort—Bleomycin—skin cancer	0.00237	0.00237	CcSEcCtD
Regadenoson—Malaise—Dactinomycin—skin cancer	0.00237	0.00237	CcSEcCtD
Regadenoson—Dysgeusia—Temozolomide—skin cancer	0.00232	0.00232	CcSEcCtD
Regadenoson—Asthenia—Imiquimod—skin cancer	0.00232	0.00232	CcSEcCtD
Regadenoson—Anaphylactic shock—Bleomycin—skin cancer	0.0023	0.0023	CcSEcCtD
Regadenoson—Nausea—Vemurafenib—skin cancer	0.00225	0.00225	CcSEcCtD
Regadenoson—Vision blurred—Temozolomide—skin cancer	0.00224	0.00224	CcSEcCtD
Regadenoson—Myalgia—Dactinomycin—skin cancer	0.00223	0.00223	CcSEcCtD
Regadenoson—Bronchospasm—Docetaxel—skin cancer	0.00223	0.00223	CcSEcCtD
Regadenoson—Tremor—Temozolomide—skin cancer	0.00222	0.00222	CcSEcCtD
Regadenoson—Diarrhoea—Imiquimod—skin cancer	0.00221	0.00221	CcSEcCtD
Regadenoson—Discomfort—Dactinomycin—skin cancer	0.00221	0.00221	CcSEcCtD
Regadenoson—Angina pectoris—Docetaxel—skin cancer	0.00221	0.00221	CcSEcCtD
Regadenoson—Ill-defined disorder—Temozolomide—skin cancer	0.0022	0.0022	CcSEcCtD
Regadenoson—Erythema—Fluorouracil—skin cancer	0.00219	0.00219	CcSEcCtD
Regadenoson—Angioedema—Temozolomide—skin cancer	0.00217	0.00217	CcSEcCtD
Regadenoson—Hypotension—Bleomycin—skin cancer	0.00215	0.00215	CcSEcCtD
Regadenoson—Malaise—Temozolomide—skin cancer	0.00214	0.00214	CcSEcCtD
Regadenoson—Dizziness—Imiquimod—skin cancer	0.00214	0.00214	CcSEcCtD
Regadenoson—Palpitations—Temozolomide—skin cancer	0.0021	0.0021	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Bleomycin—skin cancer	0.00209	0.00209	CcSEcCtD
Regadenoson—Cough—Temozolomide—skin cancer	0.00207	0.00207	CcSEcCtD
Regadenoson—Paraesthesia—Bleomycin—skin cancer	0.00206	0.00206	CcSEcCtD
Regadenoson—Vision blurred—Fluorouracil—skin cancer	0.00206	0.00206	CcSEcCtD
Regadenoson—Convulsion—Temozolomide—skin cancer	0.00206	0.00206	CcSEcCtD
Regadenoson—Vomiting—Imiquimod—skin cancer	0.00205	0.00205	CcSEcCtD
Regadenoson—Hypertension—Temozolomide—skin cancer	0.00205	0.00205	CcSEcCtD
Regadenoson—Dyspnoea—Bleomycin—skin cancer	0.00205	0.00205	CcSEcCtD
Regadenoson—Rash—Imiquimod—skin cancer	0.00204	0.00204	CcSEcCtD
Regadenoson—Dermatitis—Imiquimod—skin cancer	0.00204	0.00204	CcSEcCtD
Regadenoson—Headache—Imiquimod—skin cancer	0.00202	0.00202	CcSEcCtD
Regadenoson—Arthralgia—Temozolomide—skin cancer	0.00202	0.00202	CcSEcCtD
Regadenoson—Myalgia—Temozolomide—skin cancer	0.00202	0.00202	CcSEcCtD
Regadenoson—Anxiety—Temozolomide—skin cancer	0.00201	0.00201	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.00201	0.00201	CcSEcCtD
Regadenoson—Discomfort—Temozolomide—skin cancer	0.002	0.002	CcSEcCtD
Regadenoson—Acute coronary syndrome—Docetaxel—skin cancer	0.00199	0.00199	CcSEcCtD
Regadenoson—Renal failure—Docetaxel—skin cancer	0.00198	0.00198	CcSEcCtD
Regadenoson—Myocardial infarction—Docetaxel—skin cancer	0.00198	0.00198	CcSEcCtD
Regadenoson—Pain—Bleomycin—skin cancer	0.00196	0.00196	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.00195	0.00195	CcSEcCtD
Regadenoson—Anaphylactic shock—Temozolomide—skin cancer	0.00194	0.00194	CcSEcCtD
Regadenoson—Nausea—Imiquimod—skin cancer	0.00192	0.00192	CcSEcCtD
Regadenoson—Nervous system disorder—Temozolomide—skin cancer	0.0019	0.0019	CcSEcCtD
Regadenoson—Convulsion—Fluorouracil—skin cancer	0.00189	0.00189	CcSEcCtD
Regadenoson—Feeling abnormal—Bleomycin—skin cancer	0.00189	0.00189	CcSEcCtD
Regadenoson—Skin disorder—Temozolomide—skin cancer	0.00188	0.00188	CcSEcCtD
Regadenoson—Hyperhidrosis—Temozolomide—skin cancer	0.00187	0.00187	CcSEcCtD
Regadenoson—Chest pain—Fluorouracil—skin cancer	0.00186	0.00186	CcSEcCtD
Regadenoson—Myalgia—Fluorouracil—skin cancer	0.00186	0.00186	CcSEcCtD
Regadenoson—Discomfort—Fluorouracil—skin cancer	0.00184	0.00184	CcSEcCtD
Regadenoson—Pain—Dactinomycin—skin cancer	0.00183	0.00183	CcSEcCtD
Regadenoson—Urticaria—Bleomycin—skin cancer	0.00182	0.00182	CcSEcCtD
Regadenoson—Hypoaesthesia—Docetaxel—skin cancer	0.0018	0.0018	CcSEcCtD
Regadenoson—Anaphylactic shock—Fluorouracil—skin cancer	0.00178	0.00178	CcSEcCtD
Regadenoson—Connective tissue disorder—Docetaxel—skin cancer	0.00178	0.00178	CcSEcCtD
Regadenoson—Feeling abnormal—Dactinomycin—skin cancer	0.00176	0.00176	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Temozolomide—skin cancer	0.00176	0.00176	CcSEcCtD
Regadenoson—Insomnia—Temozolomide—skin cancer	0.00175	0.00175	CcSEcCtD
Regadenoson—Gastrointestinal pain—Dactinomycin—skin cancer	0.00175	0.00175	CcSEcCtD
Regadenoson—Nervous system disorder—Fluorouracil—skin cancer	0.00175	0.00175	CcSEcCtD
Regadenoson—Tachycardia—Fluorouracil—skin cancer	0.00174	0.00174	CcSEcCtD
Regadenoson—Paraesthesia—Temozolomide—skin cancer	0.00174	0.00174	CcSEcCtD
Regadenoson—Dyspnoea—Temozolomide—skin cancer	0.00173	0.00173	CcSEcCtD
Regadenoson—Somnolence—Temozolomide—skin cancer	0.00172	0.00172	CcSEcCtD
Regadenoson—Eye disorder—Docetaxel—skin cancer	0.00169	0.00169	CcSEcCtD
Regadenoson—Abdominal pain—Dactinomycin—skin cancer	0.00169	0.00169	CcSEcCtD
Regadenoson—Hypersensitivity—Bleomycin—skin cancer	0.00169	0.00169	CcSEcCtD
Regadenoson—Flushing—Docetaxel—skin cancer	0.00168	0.00168	CcSEcCtD
Regadenoson—Cardiac disorder—Docetaxel—skin cancer	0.00168	0.00168	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Temozolomide—skin cancer	0.00167	0.00167	CcSEcCtD
Regadenoson—Hypotension—Fluorouracil—skin cancer	0.00167	0.00167	CcSEcCtD
Regadenoson—Pain—Temozolomide—skin cancer	0.00166	0.00166	CcSEcCtD
Regadenoson—Asthenia—Bleomycin—skin cancer	0.00165	0.00165	CcSEcCtD
Regadenoson—Angiopathy—Docetaxel—skin cancer	0.00164	0.00164	CcSEcCtD
Regadenoson—Immune system disorder—Docetaxel—skin cancer	0.00164	0.00164	CcSEcCtD
Regadenoson—Mediastinal disorder—Docetaxel—skin cancer	0.00163	0.00163	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.00163	0.00163	CcSEcCtD
Regadenoson—Insomnia—Fluorouracil—skin cancer	0.00161	0.00161	CcSEcCtD
Regadenoson—Paraesthesia—Fluorouracil—skin cancer	0.0016	0.0016	CcSEcCtD
Regadenoson—Feeling abnormal—Temozolomide—skin cancer	0.0016	0.0016	CcSEcCtD
Regadenoson—Dyspnoea—Fluorouracil—skin cancer	0.00159	0.00159	CcSEcCtD
Regadenoson—Mental disorder—Docetaxel—skin cancer	0.00159	0.00159	CcSEcCtD
Regadenoson—Somnolence—Fluorouracil—skin cancer	0.00159	0.00159	CcSEcCtD
Regadenoson—Gastrointestinal pain—Temozolomide—skin cancer	0.00158	0.00158	CcSEcCtD
Regadenoson—Erythema—Docetaxel—skin cancer	0.00158	0.00158	CcSEcCtD
Regadenoson—Hypersensitivity—Dactinomycin—skin cancer	0.00158	0.00158	CcSEcCtD
Regadenoson—Dysgeusia—Docetaxel—skin cancer	0.00155	0.00155	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Fluorouracil—skin cancer	0.00154	0.00154	CcSEcCtD
Regadenoson—Urticaria—Temozolomide—skin cancer	0.00154	0.00154	CcSEcCtD
Regadenoson—Asthenia—Dactinomycin—skin cancer	0.00154	0.00154	CcSEcCtD
Regadenoson—Abdominal pain—Temozolomide—skin cancer	0.00153	0.00153	CcSEcCtD
Regadenoson—Pain—Fluorouracil—skin cancer	0.00153	0.00153	CcSEcCtD
Regadenoson—Feeling abnormal—Fluorouracil—skin cancer	0.00147	0.00147	CcSEcCtD
Regadenoson—Diarrhoea—Dactinomycin—skin cancer	0.00146	0.00146	CcSEcCtD
Regadenoson—Vomiting—Bleomycin—skin cancer	0.00146	0.00146	CcSEcCtD
Regadenoson—Rash—Bleomycin—skin cancer	0.00145	0.00145	CcSEcCtD
Regadenoson—Dermatitis—Bleomycin—skin cancer	0.00145	0.00145	CcSEcCtD
Regadenoson—Hypersensitivity—Temozolomide—skin cancer	0.00143	0.00143	CcSEcCtD
Regadenoson—Urticaria—Fluorouracil—skin cancer	0.00142	0.00142	CcSEcCtD
Regadenoson—Syncope—Docetaxel—skin cancer	0.00142	0.00142	CcSEcCtD
Regadenoson—Palpitations—Docetaxel—skin cancer	0.00139	0.00139	CcSEcCtD
Regadenoson—Asthenia—Temozolomide—skin cancer	0.00139	0.00139	CcSEcCtD
Regadenoson—Loss of consciousness—Docetaxel—skin cancer	0.00139	0.00139	CcSEcCtD
Regadenoson—Cough—Docetaxel—skin cancer	0.00138	0.00138	CcSEcCtD
Regadenoson—Convulsion—Docetaxel—skin cancer	0.00137	0.00137	CcSEcCtD
Regadenoson—Nausea—Bleomycin—skin cancer	0.00136	0.00136	CcSEcCtD
Regadenoson—Hypertension—Docetaxel—skin cancer	0.00136	0.00136	CcSEcCtD
Regadenoson—Vomiting—Dactinomycin—skin cancer	0.00136	0.00136	CcSEcCtD
Regadenoson—Rash—Dactinomycin—skin cancer	0.00135	0.00135	CcSEcCtD
Regadenoson—Arthralgia—Docetaxel—skin cancer	0.00134	0.00134	CcSEcCtD
Regadenoson—Chest pain—Docetaxel—skin cancer	0.00134	0.00134	CcSEcCtD
Regadenoson—Myalgia—Docetaxel—skin cancer	0.00134	0.00134	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.00133	0.00133	CcSEcCtD
Regadenoson—Diarrhoea—Temozolomide—skin cancer	0.00132	0.00132	CcSEcCtD
Regadenoson—Hypersensitivity—Fluorouracil—skin cancer	0.00131	0.00131	CcSEcCtD
Regadenoson—Anaphylactic shock—Docetaxel—skin cancer	0.00129	0.00129	CcSEcCtD
Regadenoson—Dizziness—Temozolomide—skin cancer	0.00128	0.00128	CcSEcCtD
Regadenoson—Nausea—Dactinomycin—skin cancer	0.00127	0.00127	CcSEcCtD
Regadenoson—Shock—Docetaxel—skin cancer	0.00127	0.00127	CcSEcCtD
Regadenoson—Nervous system disorder—Docetaxel—skin cancer	0.00126	0.00126	CcSEcCtD
Regadenoson—Tachycardia—Docetaxel—skin cancer	0.00126	0.00126	CcSEcCtD
Regadenoson—Skin disorder—Docetaxel—skin cancer	0.00125	0.00125	CcSEcCtD
Regadenoson—Vomiting—Temozolomide—skin cancer	0.00123	0.00123	CcSEcCtD
Regadenoson—Rash—Temozolomide—skin cancer	0.00122	0.00122	CcSEcCtD
Regadenoson—Diarrhoea—Fluorouracil—skin cancer	0.00122	0.00122	CcSEcCtD
Regadenoson—Dermatitis—Temozolomide—skin cancer	0.00122	0.00122	CcSEcCtD
Regadenoson—Headache—Temozolomide—skin cancer	0.00121	0.00121	CcSEcCtD
Regadenoson—Hypotension—Docetaxel—skin cancer	0.0012	0.0012	CcSEcCtD
Regadenoson—Dizziness—Fluorouracil—skin cancer	0.00118	0.00118	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Docetaxel—skin cancer	0.00117	0.00117	CcSEcCtD
Regadenoson—Insomnia—Docetaxel—skin cancer	0.00116	0.00116	CcSEcCtD
Regadenoson—Paraesthesia—Docetaxel—skin cancer	0.00116	0.00116	CcSEcCtD
Regadenoson—Nausea—Temozolomide—skin cancer	0.00115	0.00115	CcSEcCtD
Regadenoson—Dyspnoea—Docetaxel—skin cancer	0.00115	0.00115	CcSEcCtD
Regadenoson—Somnolence—Docetaxel—skin cancer	0.00114	0.00114	CcSEcCtD
Regadenoson—Vomiting—Fluorouracil—skin cancer	0.00113	0.00113	CcSEcCtD
Regadenoson—Rash—Fluorouracil—skin cancer	0.00112	0.00112	CcSEcCtD
Regadenoson—Dermatitis—Fluorouracil—skin cancer	0.00112	0.00112	CcSEcCtD
Regadenoson—Headache—Fluorouracil—skin cancer	0.00112	0.00112	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Docetaxel—skin cancer	0.00111	0.00111	CcSEcCtD
Regadenoson—Pain—Docetaxel—skin cancer	0.0011	0.0011	CcSEcCtD
Regadenoson—Feeling abnormal—Docetaxel—skin cancer	0.00106	0.00106	CcSEcCtD
Regadenoson—Nausea—Fluorouracil—skin cancer	0.00106	0.00106	CcSEcCtD
Regadenoson—Gastrointestinal pain—Docetaxel—skin cancer	0.00105	0.00105	CcSEcCtD
Regadenoson—Abdominal pain—Docetaxel—skin cancer	0.00102	0.00102	CcSEcCtD
Regadenoson—Hypersensitivity—Docetaxel—skin cancer	0.000949	0.000949	CcSEcCtD
Regadenoson—Asthenia—Docetaxel—skin cancer	0.000924	0.000924	CcSEcCtD
Regadenoson—Diarrhoea—Docetaxel—skin cancer	0.000881	0.000881	CcSEcCtD
Regadenoson—Dizziness—Docetaxel—skin cancer	0.000852	0.000852	CcSEcCtD
Regadenoson—Vomiting—Docetaxel—skin cancer	0.000819	0.000819	CcSEcCtD
Regadenoson—Rash—Docetaxel—skin cancer	0.000812	0.000812	CcSEcCtD
Regadenoson—Dermatitis—Docetaxel—skin cancer	0.000811	0.000811	CcSEcCtD
Regadenoson—Headache—Docetaxel—skin cancer	0.000807	0.000807	CcSEcCtD
Regadenoson—Nausea—Docetaxel—skin cancer	0.000765	0.000765	CcSEcCtD
